Trial Profile

Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antiretrovirals (Primary) ; Selumetinib (Primary)
Indications Kaposi's sarcoma
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms SCART

Most Recent Events

19 Mar 2025 Results(Between 15 Jun 2012 and 25 Sep 2018, n=19) identifying a safe dose for the MEK inhibitor selumetinib in combination with antiretroviral therapy (ART) and to establish evidence of the combinations efficacy , published in the BMC Cancer
18 Feb 2019 Status changed from active, no longer recruiting to discontinued.
09 Feb 2019 This trial has been completed in United Kingdom.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com